Loading...
NPI 1952517187 · Lynchburg, VA · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Landon Colling is a ophthalmology physician provider located in Lynchburg, Virginia. This profile covers 13 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Landon Colling |
| Address | 2108 Langhorne Rd |
| City | Lynchburg |
| State | VA |
| ZIP | 24501 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | May 15, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.8M |
| Medicaid | $190 |
Medicare is the dominant payer for this provider: reported lifetime Medicare revenue is $2.8M compared with just $195 in Medicaid revenue, so the practice’s clinical and financial activity is effectively concentrated in the Medicare population. The NPI has been enumerated since 2007-05-15 (~19 years ago), indicating a long-tenured Medicare billing history that aligns with a sustained outpatient ophthalmology practice model.
Revenue concentration on Medicare is highly focused: the precomputed top 3 Medicare codes account for 92.1% of this provider's total Medicare revenue, and a single code, J0178, drives the majority of that amount (3.1K claims, $690 avg paid/claim, $2.2M revenue; 78.4% of Medicare revenue). This concentration signals a business model centered on high-volume administration of aflibercept injections rather than a broad mix of low-revenue services.
Service-line implications from the top codes point to a retina-focused ambulatory practice: heavy use of J0178 (aflibercept injection), 67028 (intravitreal injection as a separate procedure), and frequent imaging with 92134 (retinal OCT, 2.6K claims, $30 avg paid/claim, $78.6K revenue). Together these codes reflect an operational workflow centered on recurring intravitreal anti-VEGF therapy with frequent monitoring visits and imaging consistent with medical retina care.
Clinical visit volume is unusually high relative to national peers: 99214 appears 2.5K times for $210.5K revenue (7.6% of Medicare revenue) and is flagged as an extreme outlier (100th percentile, far above typical national volume). Paired with elevated counts for 99213 and 92134 (both also high-percentile flags), this suggests the practice manages a large established Medicare patient panel requiring repeated evaluation-and-management visits.
Competitive standing for therapeutic injections is strong nationally: J0178 ranks #162 of 3204 providers (95th percentile; notably above typical national volume), indicating this provider is a major national participant for aflibercept administration. By contrast, other procedure ranks such as 67028 at the 90th percentile are more typical, positioning the practice as especially dominant for the drug administration component rather than for all intravitreal procedure types.
Statistical outlier signals are concentrated in E/M and retinal imaging codes: 99214 and 99213 are labeled extreme outliers (100th and 99th percentile respectively), and 92134 is also an extreme outlier (98th percentile). These labels indicate visit and monitoring volumes that are far above typical peers and should be interpreted as high utilization of office-based management and OCT surveillance in this clinician’s workflow.
Medicaid activity is negligible and narrow: total Medicaid revenue is $195 and the precomputed top-3 share is 100.0%, with all Medicaid billing represented by 92015 (13 claims, $15 avg paid/claim, $195 revenue). The Medicaid rank is #471 of 495 in-state (2nd percentile; typical, unremarkable volume), which signals minimal Medicaid participation and no substantive Medicaid-based service line.
Operational risk/strategy considerations for payers and network planners: given the extreme concentration in high-cost drug administration (J0178 at $690 avg paid/claim) and very high visit volumes (99214 extreme outlier), any changes in drug reimbursement, prior authorization, or referral patterns could materially affect practice revenue and patient access. For payers evaluating network balance, this provider functions as a high-volume Medicare retina injector with minimal Medicaid throughput, making them a specialty-focused node in the local care network rather than a general ophthalmology practice.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,130 | $690 | $2.2M |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 2,480 | $90 | $210.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,990 | $80 | $167K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,240 | $70 | $81.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,620 | $30 | $78.6K |
| J9035 | Injection, bevacizumab, 10 mg | 390 | $60 | $21.3K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 120 | $100 | $11.8K |
| 92083 | The provider may use one or more methods to determine the extent of a patient's visual field of one or both eyes; he interprets the results and prepares a report. Report this code for an extended… | 260 | $40 | $11.1K |
| 67840 | In this procedure, the provider excises a diseased or damaged area from the eyelid, excluding a chalazion, an inflamed oil gland. If necessary, he closes the wound with sutures. | 30 | $200 | $5.9K |
| 92133 | The provider performs computerized diagnostic imaging of the optic nerve in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both… | 190 | $30 | $5K |
Showing 1–10 of 13
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
13 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 9 | 80 | 1,400 | $690 | $1.1M |
| 67028 | 19 | 90 | 1,000 | $90 | $107.1K |
| 99214 | 15 | 12,890 | 140 | $80 | $21K |
| J9035 | 14 | 60 | 170 | $50 | $19.9K |
| 99213 | 109 | 12,440 | 90 | $60 | $10K |
| 92134 | 31 | 680 | 70 | $30 | $9.7K |
| 67840 | 8 | 20 | 30 | $210 | $8.8K |
| 99204 | 602 | 6,850 | 40 | $110 | $5.9K |
| 92083 | 103 | 700 | 70 | $40 | $5.7K |
| 92133 | 155 | 680 | 70 | $20 | $3.6K |
Showing 1–10 of 13
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92015 | The provider determines the process of determining if a patient's vision is less than 20/20 and by what amount so that corrective lenses or contact lenses can be prescribed and produced. | 10 | $20 | $200 |
How this provider's Medicaid billing volume and revenue compare to other Virginia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Virginia median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92015 | The provider determines the process of determining if a patient's vision is less than 20/20 and by what amount so that corrective lenses or contact lenses can be prescribed and produced. | 471 | 500 | 350 | $10 | $15.3K |
Other providers in the same ZIP code as Landon Colling, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.